EUVIMEDEUVIMED entdecken
Crossref

BLM as a potential therapeutic target in cutaneous malignant melanoma

Lidan Zhang, Gang Yu, Lei Zhang, Ye Wang, Ting Ma, Liyun Jie, Bixue Xu, Yu Cao, Heng Luo

Biochemical Pharmacology · 2026-09 · 251 · 118181

DOI: 10.1016/j.bcp.2026.118181 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical Pharmacology, 2026-09. Verfasst von Lidan Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Affiliated Hospital of Guizhou Medical University, Guiyang 550004, China; The Affiliated Jinyang Hospital of Guizhou Medic…. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, RecQ Helicases, Antineoplastic Agents. Die Arbeit nennt 44 Literaturangaben. Gefördert von: Guizhou Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Skin cutaneous melanoma (SKCM) is highly aggressive, has a poor prognosis, and readily develops drug resistance. Therefore, elucidating new mechanisms underlying the development and progression of cutaneous malignant melanoma, identifying specific new targets, and developing effective therapeutics based on these targets has become a current research priority. This study analyzed clinical tissue samples from SKCM patients, revealing that BLM DNA helicase (BLM) is highly expressed in SKCM tissues but minimally expressed in pigmented nevus tissues. Furthermore, BLM expression correlates with patient survival, highlighting its significant role in melanoma development. These findings position BLM as a promising target for anti-melanoma therapy. Building on this, a trifluoromethylpyrimidine derivative (FMD-108) targeting BLM was identified from a chemical library of natural products and derivatives developed by our team. In vitro and in vivo experiments demonstrated that FMD-108 notably inhibited cancer cell growth and metastasis, while significantly modulating the expression of DNA damage markers (γ-H2AX, p-CHK1, p-CHK2), apoptosis-related proteins (Bcl-2, Bax), and epithelial-mesenchymal transition (EMT) markers (E-cadherin, N-cadherin, Vimentin). These results suggest that FMD-108 effectively suppresses melanoma cell proliferation and metastasis by inducing apoptosis, arresting the cell cycle at the G1 phase, and inducing DNA damage. These findings suggest that BLM may serve as a potential target in cutaneous malignant melanoma, providing a prospective strategy for clinical anti-melanoma drug development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsRecQ HelicasesAntineoplastic AgentsPyrimidinesHumansAnimalsCell Line, TumorCutaneous Malignant MelanomaMiceMice, NudeXenograft Model Antitumor AssaysCell Proliferation

Stichwörter der Autor:innen

BLMDNA damageMelanomaTrifluoromethylpyrimidine derivatives

Substanzen

RecQ HelicasesBloom syndrome proteinAntineoplastic AgentsPyrimidines

Autor:innen und Institutionen

  • Department of Dermatology, Affiliated Hospital of Guizhou Medical University, Guiyang 550004, China; The Affiliated Jinyang Hospital of Guizhou Medical University, Guiyang 550081, China; State Key Laboratory of Discover…
  • State Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Medical University, Guiyang 550014, China; Natural Products Research Center of Guizhou Province, Guizho…
  • The Affiliated Jinyang Hospital of Guizhou Medical University, Guiyang 550081, China.
  • School of Nursing, Guiyang Healthcare Vocational University, Guiyang 550081, China.
  • Department of Dermatology, Guizhou Provincial People's Hospital, Guiyang 550000, China.
  • Department of Dermatology, Affiliated Hospital of Guizhou Medical University, Guiyang 550004, China.

Förderung

  • Guizhou Medical University

Zitieren

APA

Zhang, L., Yu, G., Zhang, L., Wang, Y., Ma, T., Jie, L., Xu, B., Cao, Y., & Luo, H. (2026). BLM as a potential therapeutic target in cutaneous malignant melanoma. Biochemical Pharmacology, 251, 118181. https://doi.org/10.1016/j.bcp.2026.118181

Vancouver

Zhang L, Yu G, Zhang L, Wang Y, Ma T, Jie L, et al. BLM as a potential therapeutic target in cutaneous malignant melanoma. Biochemical Pharmacology. 2026;251:118181. doi:10.1016/j.bcp.2026.118181

BibTeX
@article{Zhang2026,
  author = {Zhang, Lidan and Yu, Gang and Zhang, Lei and Wang, Ye and Ma, Ting and Jie, Liyun and Xu, Bixue and Cao, Yu and Luo, Heng},
  title = {BLM as a potential therapeutic target in cutaneous malignant melanoma},
  journal = {Biochemical Pharmacology},
  year = {2026},
  volume = {251},
  pages = {118181},
  doi = {10.1016/j.bcp.2026.118181}
}
Kostenlos starten →